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Safety and feasibility of preoperative exercise training during
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the gastro-oesophageal junction
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Background: Neoadjuvant chemotherapy or chemoradiotherapy is used widely before tumour resection
in cancer of the gastro-oesophageal junction (GOJ). Strategies to improve treatment tolerability are
warranted. This study examined the safety and feasibility of preoperative exercise training during
neoadjuvant treatment in these patients.
Methods: Patients were allocated to a standard-care control group or an exercise group, who were
prescribed standard care plus twice-weekly high-intensity aerobic exercise and resistance training
sessions. The primary endpoint was the incidence of serious adverse events (SAEs) that prevented
surgery, including death, disease progression or physical deterioration. Preoperative hospital admission,
postoperative complications, changes in patient-reported quality of life and pathological treatment
response were also recorded. In the exercise group, adherence to exercise and changes in aerobic fitness,
muscle strength and body composition were measured.
Results: The incidence of SAEs was not increased in the exercise group. The risk of failure to reach
surgery was 5 versus 21 per cent in the control group (risk ratio (RR) 0⋅23, 95 per cent c.i. 0⋅04 to 1⋅29),
the risk of preoperative hospital admission was 15 versus 38 per cent respectively (RR 0⋅39, 0⋅12 to 1⋅23)
and the risk of postoperative complications was 58 versus 57 per cent (RR 1⋅06, 0⋅61 to 1⋅73). The exercise
group attended amean of 17⋅5 sessions, and improved fitness, muscle strength and Functional Assessment
of Cancer Therapy – Esophageal (FACT-E) total score compared with the baseline level.
Conclusion: Preoperative exercise training during neoadjuvant treatment in patients with GOJ cancer is
safe and feasible, with improvements in fitness, strength and quality of life. Preoperative exercise training
may be associated with a lower risk of critical SAEs that preclude surgery or result in hospitalization.
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Introduction
Adenocarcinoma of the gastro-oesophageal junction
(GOJ) is a growing challenge, with an increasing incidence
rate and poor prognosis1,2. For many patients, surgical
removal of the primary tumour is an essential component
of treatment with intent to cure3,4. Neoadjuvant
chemotherapy or chemoradiotherapy is used widely in
patients with locally advanced or node-positive tumours
to achieve clear resection margins and improve long-term
survival5,6. Although neoadjuvant treatments have
improved long-term survival, these approaches are not
without challenges. In non-responders, there is a risk of
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disease progression, and physical deterioration and other
toxicities can increase the risk of serious postoperative
complications or prevent planned surgery due to poor
performance status. It remains a challenge to ensure that
patients with operable GOJ cancer reach surgery in good
physiological condition7.
Although neoadjuvant treatment can result in adverse
reactions, it also provides a preoperative window to coun-
teract physiological decline and improve the condition of
these patients before surgery. Preoperative exercise train-
ing has been shown to reduce the risk of complications
by up to 50 per cent in patients undergoing gastrointesti-
nal surgery8. The role of preoperative exercise remains
poorly investigated, however, with regard to tolerability of
neoadjuvant therapies that can have a profound impact on
exercise capacity, participation and adaptive responses9.
The present study explored the safety and feasibility
of high-intensity aerobic and resistance exercise during
neoadjuvant treatment in patients with GOJ cancer. The
primary objective was to examine the rates of serious
adverse events (SAEs). These SAEs included issues that
precluded surgery (death, disease progression or severe
physical deterioration). Preoperative hospital admission,
need for dose reduction or postponement, and specific
toxicities related to neoadjuvant treatment, and postoper-
ative complications were also recorded. Adherence to the
exercise prescription, involving attendance rate, number
of interruptions and exercise modifications, and changes
in aerobic fitness, muscle function and body composition
were also determined. It was hypothesized that preopera-
tive exercise training would be safe (would not increase the
risk of SAEs compared with standard care) and feasible,
resulting in improved cardiopulmonary and muscular
fitness levels.
Methods
This was a prospective, controlled, feasibility study based at
Rigshospitalet, Copenhagen University Hospital. Patients
with histologically verified, resectable adenocarcinoma
of the GOJ were eligible for inclusion. Major exclusion
criteria were: age below 18 or more than 80 years; inoper-
ability based on imaging; pregnancy; presence of any other
known malignancy requiring active treatment; ineligibility
for neoadjuvant treatment; WHO performance status
greater than 1; physical or mental disabilities precluding
physical testing and/or exercise; and inability to read
and understand Danish. The study was approved by the
local ethics committee (H-17003961) and registered with
Clinicaltrials.gov (NCT02722785).
Patients were recruited from the Department of Sur-
gical Gastroenterology, Rigshospitalet, a large-volume
centre responsible for treatment of operable GOJ can-
cer for the whole of Eastern Denmark. Eligible patients
were informed of the study during their first visit to the
outpatient clinic following a multidisciplinary medical
conference, and provided signed informed consent before
any study-related procedures were performed.
Standard gastro-oesophageal junction cancer
treatment
All eligible subjects were scheduled to receive standard of
care at Rigshospitalet. This consisted of three neoadjuvant
cycles of chemotherapy at intervals of 3weeks followed by
surgery and three further cycles of adjuvant chemother-
apy. Each cycle of chemotherapy consisted of epirubicin
(Pharmachemie, Haarlem, the Netherlands) 50mg/m2
intravenously on day 1, capecitabine (Accord Healthcare,
Harrow, UK) 500mg/m2 orally twice daily for 21 days
and either cisplatin (Hospira UK, Hurley, UK) 60mg/m2
intravenously (ECX) or oxaliplatin (Fresenius Kabi Oncol-
ogy, Bordon, UK) 130mg/m2 on day 1 (EOX)10. Owing
to participation in another RCT, some patients received
treatment according to the CROSS regimen11, involv-
ing five cycles of paclitaxel (Fresenius Kabi Oncology)
50mg/m2 and carboplatin (Fresenius Kabi Oncology)
intravenously in doses titrated to achieve an area under
the curve of 2mg per ml per min given once a week
concurrently with radiotherapy, 41⋅4Gy in 23 fractions,
5 days per week.
Surgery was performed 4–6weeks after the comple-
tion of neoadjuvant therapy. The Ivor Lewis procedure
was used consistently throughout the study, performed
either as robot-assisted minimally invasive oesophagec-
tomy, hybrid (robot-assisted laparoscopy combined with
thoracotomy) or open (laparotomy and thoracotomy), as
described previously12.
Group allocation
Participants were enrolled to one of two study arms with-
out randomization, based on their geographical residen-
tial location; subjects residing within a predefined area
of the Greater Copenhagen region were allocated to the
exercise group and those residing outside this area were
allocated to a standard-care control group. All subjects who
agreed to participate performed a series of baseline tests
during an outpatient clinic visit. This included evaluation
of lower-body physical function by the 30-s sit-to-stand
test and of upper-body physical function by handgrip
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strength using a hand-held dynamometer. Body compo-
sition was measured by bioelectrical impedance analysis
using a Bioelectrical Impedance Analyzer (MC-780 MA;
Tanita, Tokyo, Japan). The skeletal muscle index (SMI),
defined as total cross-sectional transverse muscle area (cm2
at the L3 region normalized to height; cm2/m2), was
measured on available CT scans using OsiriX (v 3.5.1,
32-bit; http://www.osirix-viewer.com)13.
Participants residing outside the predefined area of
Greater Copenhagen, enrolled in the usual-care control
group, had to travel for at least 45min (up to 2 h) to reach
the hospital; this was considered unfeasible for partic-
ipation in a hospital-based training programme. These
patients followed the standard of care delivered by the
Departments of Oncology and Surgical Gastroenterology,
which included information regarding smoking cessation,
diet, alcohol and physical activity guidelines through
consultations with clinical dieticians and nurse specialists.
Those in the control group were allowed to participate
in any standard hospital or municipality-based exercise
programmes.
Participants residing within the Greater Copenhagen
area were allocated to supervised training intervention
at the Centre for Physical Activity Research, Rigshospi-
talet. The training programme consisted of supervised
high-intensity aerobic and resistance exercise with
twice-weekly sessions of approximately 75min (Fig.S1,
supporting information). Individual fitness and strength
capacity were used to personalize the programme. Each
session included a 10-min warm-up on a stationary bicycle
followed by 21–28min of high-intensity interval training
consisting of 4× 4min with 3min of low-intensity active
recovery between each high-intensity bout. Resistance
training comprised four exercises for the major muscle
groups: chest press, leg press, lateral pull and knee exten-
sion, with one warm-up set followed by three sets of
8–12 repetitions. Each session was supervised by a trained
instructor to ensure proper technique, and progression in
training load.
Assessments and study endpoints
The primary outcome measure was the frequency of SAEs,
defined as events that prevented surgery: death, verified
disease progression due to the development of distant
metastasis or local tumour invasion to nearby structures
preventing radical tumour resection, or severe physical
deterioration following neoadjuvant treatment, leading to
a joint decision between patient and surgeon (not involved
in the study) that the patient was unfit for oesophagectomy.
Secondary endpoints included assessment of neoadjuvant
treatment tolerability involving: non-scheduled preopera-
tive hospitalization (for more than 24 h), dose reduction,
postponement of scheduled neoadjuvant treatment, and
incidence of grade 1–4 toxicities according to Common
Toxicity Criteria (CTC). Postoperative complications were
graded according to the Clavien–Dindo classification14;
‘all complications’ were defined as Clavien–Dindo grade
II or above, and ‘serious complications’ as Clavien–Dindo
grade III or above. A comprehensive complication index
(CCI) score was calculated as described previously15 and
postoperative duration of hospital stay was determined.
Patient-reported tolerability to neoadjuvant treatment
was assessed by changes in health-related quality of life
from baseline to the day before scheduled surgery using the
Functional Assessment of Cancer Therapy – Esophageal
(FACT-E) questionnaire16.
Response to treatment was measured by infiltration
of the resection margin (R0, R1, R2)17 and analysis
of resected tumours for intratumoral T-cell densities
(immunoscore), tumour regression grade and pathological
tumour stage (pTNM) as described previously byMandard
and colleagues18.
Feasibility and efficacy of preoperative exercise
training
Feasibility of exercise training was assessed by adherence
to the prescribed programme, including registration of the
following metrics: attendance rate, occurrence of exercise
modification (dose reduction or early termination of
individual sessions), training interruption and permanent
discontinuation19. The number of attended sessions was
recorded for each participant and the adherence rate was
determined as the number of planned sessions attended.
Exercise dose modification was defined as the number of
sessions with a reduction in volume or intensity from the
prescribed session, as well as instances of early termination
before the full programme had been performed. Training
interruption was defined as a period of 7 days or more
without a training session. Permanent discontinuation was
noted if participants withdrew entirely from the exercise
programme, regardless of whether they remained in the
study.
For every session, an instructor was present to super-
vise the exercise programme. Participants were asked about
common adverse reactions (fatigue, nausea, pain and dizzi-
ness) before the start of every session, and after each session
any notable changes (improvement, unchanged or worsen-
ing) were recorded.
Participants in the exercise group were evaluated for
changes in cardiopulmonary fitness, muscle strength and
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All candidates screened during study interval n=234
All eligible participants n=62
Available for analysis
Treatment failure (ITT) n=21
Neoadjuvant treatment complications n=20
Patient-reported outcomes n=20
Postoperative complications n=19
Treatment response n=19
Available for analysis
Treatment failure (ITT) n=29
Neoadjuvant treatment complications n=26
Patient-reported outcomes n=26
Postoperative complications n=23
Treatment response n=23
Excluded n=6
 Not interested n=3
 Not able to exercise n=3
Excluded n=3
 Poor condition n=1
 Died n=1
 Disease progression n=1
Ineligible n=172
 Not surgical candidate n=52
 Not GOJ adenocarcinoma n=41
 No cancer n=37
 No neoadjuvant treatment n=18
 Not Danish-speaking n=8
 Other active cancer (required treatment) n=6
 Physical or mental disability n=5
 Age >80 years n=3
 No reason given n=2
Eligible for exercise group n=27
Included in exercise group n=21
Scheduled for surgery n=21 Scheduled for surgery n=26
Tumour resection n=20 Tumour resection n=23
Unresectable n=3
Included in control group n=29
    Preoperative exercise training
Pre-exercise test n=21
 Permanently discontinued n=3
Postexercise test n=18
Excluded n=6
 Not interested n=6
Excluded n=1
 Withdrew consent n=1
Unresectable n=1
Eligible for control group n=35
Fig. 1 Flowchart for the study, based on intention-to-treat (ITT) numbers. One participant in the exercise group who received the
scheduled treatment withdrew consent, and therefore no data are available for treatment complications or response. GOJ,
gastro-oesophageal junction
body composition before and after the intervention. Fat
mass, bone mass, fat-free mass and bone mineral density
were analysed by whole-body dual-energy X-ray absorp-
tiometry (DEXA) (DPX-IQ; LunarCorporation,Madison,
Wisconsin, USA)20. Muscle strength was evaluated by the
one-repetition maximum (1RM) test in resistance train-
ing machines (Technogym Runrace, Gambettola, Italy).
Participants were positioned correctly in the machine
and performed eight repetitions on a light load. After a
short rest, progressively higher loads were added and the
participant performed one repetition on each load. The
procedure was repeated until the single repetition could
not be completed with proper technique. The load of
the last successful repetition was noted as the test score.
Fitness was assessed using the Wattmax test on an elec-
tronically braked bicycle ergometer (Monark Ergomedic
839E Bicycle; Monark, Varberg, Sweden). Participants
performed a 3-min warm-up on a workload of 50W,
and then undertook a graded Wattmax test with a 20-W
incremental load added every minute until exhaustion.
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Table 1 Participant characteristics
All participants
(n=50)
Exercise group
(n=21)
Control group
(n=29) P
Age (years)* 64⋅8(7⋅7) 63⋅9(8⋅2) 65⋅5(7⋅3) 0⋅464
Sex ratio (M : F) 45 : 5 18 : 3 27 : 2 0⋅638
BMI (kg/m2)* 28⋅1(5⋅5) 28⋅4(5⋅6) 27⋅8(5⋅5) 0⋅717
Diabetes 9 (18) 5 (24) 4 (14) 0⋅464
Cardiovascular disease 6 (12) 3 (14) 3 (10) 0⋅686
ASA grade
0 4 (8) 3 (14) 1 (3) 0⋅211
I 12 (24) 7 (33) 5 (17)
II 26 (52) 8 (38) 18 (62)
III 8 (16) 3 (14) 5 (17)
Smoker
Current 10 (20) 1 (5) 9 (31) 0⋅041
Previous 29 (58) 16 (76) 13 (45)
Never 11 (22) 4 (19) 7 (24)
Alcohol intake (units/week)†
≤7 or ≤14 42 (84) 19 (90) 23 (79) 0⋅441
>7 or >14 8 (16) 2 (10) 6 (21)
Physical activity level (min MVPA/week)
<150 38 (76) 17 (81) 21 (72) 0⋅526
≥150 12 (24) 4 (19) 8 (28)
cTNM stage
I 5 (10) 2 (10) 3 (10) 0⋅691
II 30 (60) 14 (67) 16 (55)
III 15 (30) 5 (24) 10 (34)
Physical function*
Sit-to-stand performance (repetitions) 13⋅2(3⋅8) 13⋅9(3⋅6) 12⋅7(3⋅9) 0⋅298
Hand-grip strength (kg) 41⋅1(9⋅9) 39⋅8(7⋅6) 42⋅0(11⋅4) 0⋅456
Body composition (bioelectrical impedance analyses)*
Lean body mass (kg) 62⋅8(9⋅9) 62⋅1(10⋅6) 63⋅2(9⋅6) 0⋅740
Fat percentage (%) 25⋅3(8⋅6) 26⋅0(8⋅7) 25⋅7(8⋅7) 0⋅605
Skeletal muscle index (cm2/m2)* 53⋅7(8⋅8) 52⋅8(9⋅2) 54⋅2(8⋅6) 0⋅589
Neoadjuvant treatment‡ n=46 n=20 n=26
ECX 18 (39) 8 (40) 10 (38) 0⋅864
EOX 22 (48) 10 (50) 12 (46)
CROSS 6 (13) 2 (10) 4 (15)
Surgical procedure§ n=42 n=19 n=23
RAMIE 2 (5) 0 (0) 2 (9) 0⋅227
Hybrid (laparoscopy, thoracotomy) 7 (17) 2 (11) 5 (22)
Open (Ivor Lewis) 33 (79) 17 (89) 16 (70)
Values in parentheses are percentages unless indicated otherwise; *values are mean(s.d.). †Presented as adherence to the Danish national guidelines of 7
units or less for women and 14 units or less for men per week. ‡Four subjects not included owing to exclusion/withdrawal before or during neoadjuvant
treatment; §eight subjects not included owing to exclusion/withdrawal and no surgery performed. MVPA, moderate to vigorous physical activity; ECX,
epirubicin + cisplatin + capecitabine; EOX, epirubicin + oxaliplatin + capecitabine; CROSS, paclitaxel + carboplatin + radiotherapy; RAMIE,
robot-assisted minimally invasive oesophagostomy.
Participants’ peak performance (Wattmax) was applied
to estimate cardiopulmonary fitness level, peak oxygen
consumption (VO2peak, ml oxygen per min per kg) using
the standard formula proposed by the American College
of Sports Medicine, for metabolic equations21.
Statistical analysis
The feasibility study aimed to include a minimum of
20 subjects in each of the two arms without a power
calculation. Baseline comparison between the two arms was
performed using Student’s unpaired t test for continuous
variables and the χ2 test for categorical variables. Treatment
tolerability variables are presented as absolute risk for each
group, and explorative analyses of the between-group risk
ratio with 95 per cent confidence intervals were calculated
using χ2 or Fisher’s exact test. Patient-reported outcomes
(FACT-E scores) were analysed for in-group changes with
95 per cent confidence intervals from baseline to surgery
using Student’s paired t test, and between-group differ-
ences for change scores were estimated with Student’s
unpaired t test.
For the exercise group, adherence to the exercise
programme was determined by mean attendance rate, and
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Table 2 Treatment tolerability
All participants
(n=50)
Exercise group
(n=21)
Control group
(n=29) Risk ratio*
Treatment failure (intention to treat)
No. of patients precluded from surgery 7 (14) 1 (5) 6 (21) 0⋅23 (0⋅04, 1⋅29)
No. of deaths 1 0 1 –
Disease progression 5 1 4 –
Deconditioning 1 0 1 –
Complications of neoadjuvant treatment n=46 n=20 n=26
Preoperative hospitalization 13 (28) 3 (15%) 10 (38) 0⋅39 (0⋅12, 1⋅23)
Total days 78 29 49 –
Treatment dose reduction 15 (33) 6 (30) 9 (35) 0⋅87 (0⋅40, 2⋅03)
Treatment postponed 12 (26) 6 (30) 6 (23) 1⋅30 (0⋅49, 3⋅42)
Total events 14 7 7 –
CTC toxicity grade 11 (24) 3 (15) 8 (31) 0⋅45 (0⋅14, 1⋅47)
1–2 10 2 8 –
3–4 1 1 0 –
Postoperative complications n=42 n=19 n=23
All complications‡ 24 (57) 11 (58) 13 (57) 1⋅02 (0⋅61, 1⋅73)
Serious complications§ 9 4 5 –
Anastomotic leak 3 1 2 –
Pneumonia 7 4 3 –
CCI score† 20⋅9 (0–47⋅3) 20⋅9 (0–33⋅5) 20⋅9 (0–26⋅2) –
Postoperative duration of hospital stay (days)† 9 (8⋅5–11) 10 (9–11) 9 (8–11) –
Values in parentheses are percentages unless indicated otherwise; *values in parentheses are 95 per cent confidence intervals. †Values are median (i.q.r.).
‡Defined as events with Clavien–Dindo grade II or above; §defined as events with Clavien–Dindo grade II or above. CTC, Common Toxicity Criteria;
CCI, comprehensive complication index.
Table 3 Patient-reported outcomes
Change in score from baseline to surgery
All participants
(n=46)
Exercise group
(n=20)
Control group
(n=26) Mean difference
Physical wellbeing −0⋅4 (−1⋅8, 4⋅5) 1⋅2 (−0⋅9, 3⋅2) −1⋅6 (−3⋅5, 0⋅2) 2⋅8 (0⋅1, 5⋅5)
Social wellbeing 0⋅0 (−0⋅9, 1⋅0) 0⋅0 (−1⋅5, 1⋅5) 0⋅0 (−1⋅3, 1⋅5) 0⋅0 (−2⋅1, 2⋅0)
Emotional wellbeing 1⋅8 (0⋅7, 2⋅9) 3⋅0 (1⋅1, 4⋅9) 0⋅9 (−0⋅3, 2⋅1) 2⋅1 (−0⋅6, 4⋅2)
Functional wellbeing −0⋅1 (−1⋅8, 1⋅6) −0⋅4 (−3⋅6, 2⋅8) 0⋅2 (−1⋅7, 2⋅0) −0⋅6 (−4⋅0, 2⋅8)
Oesophageal cancer subscale 5⋅1 (1⋅5, 8⋅7) 8⋅8 (3⋅8, 13⋅9) 2⋅3 (−2⋅7, 7⋅2) 6⋅6 (−0⋅4, 13⋅6)
FACT-E trial outcome index 4⋅6 (−0⋅9, 10⋅1) 9⋅6 (1⋅0, 18⋅1) 0⋅8 (−6⋅6, 8⋅2) 8⋅8 (−2⋅1, 19⋅8)
FACT-G total 1⋅3 (−2⋅6, 5⋅3) 3⋅7 (−3⋅3, 10⋅8) −0⋅5 (−5⋅3, 4⋅2) 4⋅3 (−3⋅7, 12⋅2)
FACT-E total 6⋅4 (−0⋅1, 13⋅0) 12⋅6 (2⋅7, 22⋅9) 1⋅8 (−6⋅9, 10⋅4) 10⋅8 (−2⋅1, 23⋅8)
Values are mean (95 per cent c.i.). FACT-E/G, Functional Assessment of Cancer Therapy – Esophageal/General.
the absolute risk (at least 1 case) of exercise interruption
and dose modification. In-group changes in aerobic fit-
ness, muscle strength and body composition from before
to after the intervention were calculated with 95 per cent
confidence intervals using Student’s paired t test.
Results
Between 1 April 2016 and 1 May 2017, 237 potential can-
didates were screened for eligibility. Owing to an uneven
recruitment rate, subjects were enrolled in both arms until
a minimum of 20 subjects had been included in each arm.
Sixty-two candidates were eligible for inclusion, 27 in the
exercise group and 35 in the control group. Of these, 21
(78 per cent) were included in the exercise group and 29
(83 per cent) in the control group (Fig. 1). The mean(s.d.)
age of participants was 64⋅8(7⋅7) years, their BMI was
28⋅1(5⋅5) kg/m2, and 90 per cent were men. There was a
higher proportion of smokers in the control group than
in the exercise group (P= 0⋅041), but no significant dif-
ferences in scheduled neoadjuvant treatments or surgical
procedures (Table 1).
Treatment tolerability and response
Data for treatment tolerability are presented in Table 2.
The risk of treatment failure in the exercise group was 5
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Fig. 2 Schematic overview of adherence to exercise, showing individual exercise attendance, interruptions and modifications for each
subject in the exercise group, including the timing of concurrent neoadjuvant treatment
per cent, compared with 21 per cent in the control group
(risk ratio (RR) 0⋅23, 95 per cent c.i. 0⋅04 to 1⋅29). During
neoadjuvant treatment, the risk of hospital admission was
15 and 38 per cent respectively (RR 0⋅39, 0⋅12 to 1⋅23).
The rate of reduction in neoadjuvant treatment dosage was
30 per cent in the exercise group versus 35 per cent in the
control group (RR 0⋅87, 0⋅40 to 2⋅03), and the rate of treat-
ment postponement was 30 and 23 per cent respectively
(RR 1⋅30, 0⋅49 to 3⋅42). The risk of presenting with CTC
grade 1–4 toxicity was 15 per cent in the exercise group and
31 per cent in the control group (RR 0⋅45, 0⋅14 to 1⋅47).
The risk for all postoperative complications was 58 per
cent in the exercise group compared with 57 per cent in
the control group (RR 1⋅06, 95 per cent c.i. 0⋅61 to 1⋅73).
The median postoperative duration of hospital stay was
10 days in the exercise group versus 9 days in the control
group. There were three anastomotic leaks overall (1 in
the exercise group and 2 in the control group), and seven
patients developed pneumonia (4 and 3 patients respec-
tively). The median CCI score was 20⋅9 (i.q.r. 0–47⋅3).
Data for treatment response, including surgical clearance
rate (R0), tumour immunoscore, tumour regression grade
and pTNM stage, are presented in Table S1 (supporting
information).
From baseline to surgery, participants in the exercise
group reported significant improvements in the emotional
wellbeing subscale (+3⋅0, 95 per cent c.i. 1⋅1 to 4⋅9) and
the oesophageal cancer subscale (+8⋅8, 3⋅8 to 13⋅9) of
the FACT-E questionnaire. In addition, the FACT-E trial
outcome index score (+9⋅6, 1⋅0 to 18⋅1) and FACT-E
total score (+12⋅6, 2⋅7 to 22⋅9) improved in the exercise
group. No changes were observed in the control group for
patient-reported outcomes (Table 3) and only the change
in physical wellbeing differed significantly between the
groups (mean difference 2⋅8, 0⋅1 to 5⋅5).
Feasibility of preoperative exercise training
Data for adherence to preoperative exercise training
are shown in Fig. 2. Participants in the exercise group
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Table 4 Efficacy of exercise training
Physiological
endpoints
Before
exercise*
After
exercise* Mean difference†
Fitness
Peak power (W) 153⋅2(63⋅5) 165⋅2(52⋅1) +12 (0⋅1, 24⋅0)
VO2peak (ml per min
per kg)
25⋅23(8⋅38) 26⋅62(6⋅78) +1⋅39 (0⋅03, 2⋅74)
Muscle strength, 1RM
Leg press (kg) 116⋅4(27⋅8) 143⋅9(30⋅3) +26⋅9 (17⋅6, 36⋅3)
Knee extension (kg) 50⋅1(10⋅8) 60⋅4(13⋅1) +9⋅9 (6⋅2, 13⋅7)
Chest press (kg) 31⋅3(9⋅7) 36⋅8(12⋅8) +5⋅1 (2⋅7, 7⋅6)
Row (kg) 59⋅2(14⋅3) 68⋅9(16⋅5) +8⋅9 (5⋅4, 12⋅4)
Body composition,
dual-energy X-ray
absorptiometry scan
Lean body mass (kg) 55⋅6(10⋅4) 57⋅0(10⋅7) −0⋅1 (−1⋅0, 0⋅8)
Fat mass (kg) 29⋅6(13⋅4) 32⋅0(12⋅5) −0⋅3 (−1⋅8, 3⋅1)
Fat percentage (%) 33⋅6(9⋅3) 35⋅1(7⋅6) −0⋅4 (−1⋅8, 0⋅9)
Values are mean(s.d.); †values in parentheses are 95 per cent confidence
intervals. VO2peak, peak oxygen consumption; 1RM, 1-repetition
maximum.
had a mean(s.d.) attendance of 17⋅5(8⋅7) sessions,
corresponding to 68⋅7 per cent of the prescribed pro-
gramme, and three of the 21 participants permanently
discontinued the programme. Overall, participants were
able to follow the exercise prescription regarding vol-
ume and progression for exercise intensity (Table S2,
supporting information), although 94 of the total 365
sessions (25⋅8 per cent) required dose reduction (85 ses-
sions) or early termination (9 sessions) compared with
the programme prescribed for that session (Table S3,
supporting information).
During the preoperative period, a high prevalence of
self-reported symptoms was recorded before the exercise
sessions, including fatigue (21 patients; 148 sessions (42⋅9
per cent)), nausea (14 patients; 84 sessions (23⋅4 per
cent)), pain (16 patients; 112 sessions (32⋅5 per cent))
and dizziness (13 patients; 58 sessions (16⋅8 per cent)).
Participants reported worsening of these pre-exercise
symptoms in 0⋅9–3⋅5 per cent of all sessions, with reported
improvement in symptom burden in 3⋅8–14⋅2 per cent
of the sessions after acute exercise (Table S3, supporting
information).
Changes in physiological endpoints from before to after
the intervention are presented in Table 4. There were
significant improvements in: peak power (+12 (95 per
cent c.i. 0⋅1 to 24) W), corresponding to a+ 1⋅39 (0⋅03
to 2⋅74) ml oxygen per kg per min improvement in
estimated VO2peak; muscle strength for leg press (+26⋅9
(17⋅6 to 36⋅3) kg); knee extension (+9⋅9 (6⋅2 to 13⋅7)
kg); chest press (+5⋅1 (2⋅7 to 7⋅6) kg) and seated row
(+8⋅9 (5⋅4 to 12⋅4) kg). There were no changes in body
composition.
Discussion
The principal finding of this study is that high-intensity
exercise training performed during neoadjuvant treatment
was safe and feasible and led to improved aerobic fitness,
strength and health-related quality of life. Preoperative
exercise may be associated with a lower risk of treatment
failure and preoperative hospital admission during neoad-
juvant treatment, which could have important implications
for future perioperative management of patients with GOJ
cancer22,23.
Over the past decade, physical exercise has been explored
extensively to improve symptom control through better
physical capacity and psychosocial wellbeing in the oncol-
ogy setting. During the same period, preclinical studies
have reported that exercise may be associated with direct
anticancer mechanisms and the capacity to modulate thera-
peutic efficacy of traditional treatment regimens24–26. Few
clinical studies have, however, reported treatment-related
endpoints including measures of treatment tolerability and
response. The present study demonstrated considerable
reduction in the risk of treatment failure in the exercise
group compared with the control group (5 versus 21 per
cent respectively). This is arguably the single most impor-
tant outcome for patients undergoing neoadjuvant treat-
ment, as the chances of long-term survival fall significantly,
from a 5-year relative survival rate of 20–40 per cent in
operable patients to less than 5 per cent in inoperable
patients27.
Satisfactory tolerability to neoadjuvant treatment is criti-
cal in patients with GOJ cancer in order to justify the delay
before surgery. It was necessary, therefore, to determine
whether participation in exercise training would increase
the risk of SAEs during the preoperative period. In fact,
the risk of preoperative hospital admission in the exercise
group (15 versus 38 per cent in the control group) and regis-
tered CTC toxicity (15 versus 31 per cent respectively) were
halved relative to values in the control group. Improve-
ment in several domains of the FACT-E questionnaire in
the exercise group emphasized that exercise participation is
safe, and possibly beneficial, with regard to treatment tol-
erability.
If preoperative exercise does improve treatment tolera-
bility, this may translate into improved tumour response in
the preoperative period. Recent experimental studies25,26
have shown that exercise can induce a synergistic anti-
cancer effect when administered in conjunction with regu-
lar therapies. A 6-week programme of preoperative aerobic
exercise during neoadjuvant radiotherapy was associated
with a greater likelihood of response to radiotherapy in
patients with rectal cancer28. Although the present study
was probably too small to reveal any differences in response
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as evaluated by tumour regression grade and pTNM stage,
these other observations indicate that exercise may aug-
ment the response to chemotherapy and/or radiotherapy.
This might be related to improved intratumoral blood
perfusion with reductions in hypoxia, changes in tumour
metabolism, enhancement of the immunogenic profile and
inhibition of the metastatic process9. A few clinical trials
have reported prognostic data to elucidate whether such
additive and/or synergetic anticancer effects can be accom-
plished in patients with cancer. In the START trial, Cour-
neya and colleagues29 found that women with early-stage
breast cancer who performed resistance training had higher
chemotherapy completion rates compared with controls
receiving usual care. The same authors found that par-
ticipation in aerobic or resistance training was associ-
ated with a non-significant 40 per cent reduction in the
recurrence-free interval (RFI). Subgroup analyses revealed
that the exercise-induced improvement in RFI was con-
fined to patients who had received more than 85 per cent of
planned dosage, with no apparent effect in patients receiv-
ing less than this dose30.
Establishing adherence and efficacy of a structured,
high-intensity exercise programme during chemother-
apy or chemoradiotherapy was an important secondary
objective in the present study. A recent study31 reported
an average loss of 5 kg lean body mass in patients with
oesophageal cancer undergoing neoadjuvant treatment,
tripling the number of patients with sarcopenia, an inde-
pendent predictor of postoperative complication risk32
and poor long-term prognosis33. Maintained lean body
mass, combined with improvements in fitness and muscle
strength, in the exercise group are important findings in
the present study. Overall, the exercise group followed the
prescribed programme with regard to attendance, dose
and intensity, but relatively high rates of modification and
interruption were needed. This suggests that patients with
coexisting morbidities undergoing symptom-heavy thera-
pies require close monitoring and individualization of the
programme in order to optimize exercise participation and
output. Patient-reported fatigue, pain, nausea and dizzi-
ness before and after each training session did not seem
to indicate that patient-reported symptoms hampered
participation in exercise.
Recently, preoperative exercise interventions have gained
momentum in the context of prehabilitation34, but consen-
sus is lacking regarding the overall aim, content and orga-
nizational setup of such programmes. A recent Cochrane
review35 showed that preoperative exercise training can
lower risk of pulmonary complications in patients with
non-small cell lung cancer, and personalized prehabilita-
tion with aerobic exercise was found to lower complication
risk by 50 per cent after major gastrointestinal surgery8.
In the present study, postoperative complication risk was
no different in the exercise group compared with controls,
despite improvements in physiological performance. This
may reflect the small numbers of patients and relatively
few serious complications in both groups, including anas-
tomotic leakage (3 patients) and pneumonia (7 patients).
The imbalance in presurgical dropouts (1 in the exercise
group versus 6 in the control group) may also have influ-
enced postoperative outcomes, as a larger proportion of
potentially high-risk patients did not undergo surgery in
the control group.
The present study has important limitations. Most
notably, it has a limited sample size and non-randomized
design, which was chosen to improve accrual rates while
still enabling a non-exercise group to be used as reference
before potentially launching a large-scale randomized trial.
The findings of the present study should therefore be inter-
preted with care, given the multitude of factors influencing
treatment tolerability, particularly from a non-randomized
feasibility study. There may have been systematic differ-
ences between the two study arms, given the pragmatic
decision to use a non-randomized parallel-group design
including subjects from rural and urban areas for the two
arms. This may have led to socioeconomic differences, as
there was a higher proportion of smokers in the control
(rural) group. The inclusion only of patients withGOJ ade-
nocarcinoma limits the generalizability of the results. The
decision not to include other oesophageal carcinomas was
made mainly for logistical reasons, but also to minimize
the already large number of confounding variables within
an explorative pilot study. The control group received
no face-to-face attention, and the potential psychosocial
effects of interacting with health professionals/trainers
cannot be separated from the direct exercise effects.
Although the findings of the present study should be con-
sidered preliminary, preoperative exercise training should
be examined with the objective of improving treatment
tolerability and lowering the risk of treatment failure in
patients with GOJ cancer in a definitive RCT.
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